Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
(NasdaqGM:STRO), – Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC – – Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 – – Investor webcast today at 7:00AM PT / 10:00AM ET – SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Sutro Biopharma, […]